

AMENDMENTS TO THE SPECIFICATION

Column 4, beginning at line 57:

“The present invention achieves the above objects, among others, and overcomes the limitations of the prior art by providing, [an] in a preferred embodiment, drugs having chemotherapeutic properties which are useful against certain neoplastic disorders with wide safety margins as evidence by their low toxicity, and molecular actions. Such drugs include as active ingredients one or more N-substituted 2-(1H) pyridone(s) and/or N-substituted 3-(1H) pyridone(s). The compositions of this invention are novel as anti-neoplastic drugs, namely as an agent for treating malignant neoplasms (such as leukemias and lymphomas, and/or benign neoplasms (such as leiomyomas).”